Anti-cancer characteristics of mevinolin against three different solid tumor cell lines was not solely p53-dependent

References

• El-Shemy HA, Aboul-Enein AM, Aboul-Enein KM, Fujita K. Willow leaves’ extracts contain anti-tumor agents effective against three cell types. Plos one 2007;2:e178.
   PubMed Web of Science ®Google Scholar
• Nassr-Allah AA, Aboul-Enein AM, Aboul-Enein KM, Lightfoot DA, Cocchetto A., El-Shemy HA. Anti-cancer and anti-oxidant activity of some Egyptian medicinal plants. J Med Plants Res 2009; 3: 799–808.
   Web of Science ®Google Scholar
• Hong MY, Seeram NP, Zhang Y, Heber D. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. j Nutr Biochem 2008;19:448–458.
   PubMed Web of Science ®Google Scholar
• Kumari HP, Naidu KA, Vishwanatha S, Narasimhamurthy K, Vijayalakshmi G. Safety evaluation of Monascus purpureus red mould rice in albino rats. Food Chem Toxicol 2009;47:1739–1746.
   PubMed Web of Science ®Google Scholar
• Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci usa 1990;87:8931–8934.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang Y, Lv TJ, Zhou LQ, Jin J. [Effects of clinically effective dose of lovastatin on prostate cancer PC3 cells]. Beijing Da Xue Xue Bao 2010;42:391–395.
   Google Scholar
• Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int j Cancer 2006;118:773–779.
   PubMed Web of Science ®Google Scholar
• Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116:3389–3398.
   PubMed Web of Science ®Google Scholar
• Self TH, Akins D. Dramatic reduction in lipoma associated with statin therapy. j Am Acad Dermatol 2008;58:S30–S31.
   Google Scholar
• Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD et al. The association between statins and cancer incidence in a veterans population. j Natl Cancer Inst 2008;100:134–139.
   PubMed Web of Science ®Google Scholar
• Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D et al. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008;74:476–484.
   Google Scholar
• Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S et al. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int j Mol Med 2009;24:633–643.
   Google Scholar
• Klawitter J, Shokati T, Moll V, Christians U, Klawitter J. Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 2010;12:R16.
   PubMed Web of Science ®Google Scholar
• Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, Fouad F et al. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J Pharmacol Exp Ther 2010;333:23–33.
   Google Scholar
• Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101–1110.
   PubMed Web of Science ®Google Scholar
• Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 Suppl 4:1–7.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–717.
   PubMed Web of Science ®Google Scholar
• Licata S, Saponiero A, Mordente A, Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 2000;13:414–420.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–1112.
   PubMed Web of Science ®Google Scholar
• Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990;93:125–128.
   PubMed Web of Science ®Google Scholar
• Hong MY, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food 2008;11:657–666.
   Google Scholar
• Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun 2008;374:309–314.
   PubMed Web of Science ®Google Scholar
• Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004;229:567–585.
   PubMed Web of Science ®Google Scholar
• Sánchez CA, Rodríguez E, Varela E, Zapata E, Páez A, Massó FA et al. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008;26:698–707.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006;57:155–164.
   PubMed Web of Science ®Google Scholar
• Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 2008;75:907–913.
   PubMed Web of Science ®Google Scholar
• Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 2008;31:369–374.
   PubMed Web of Science ®Google Scholar
• Lee SK, Kim YC, Song SB, Kim YS. Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun 2010;391:1592–1597.
   PubMed Web of Science ®Google Scholar
• Milkevitch M, Jeitner TM, Beardsley NJ, Delikatny EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. Biochim Biophys Acta 2007;1771:1166–1176.
   Google Scholar
• Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010;10:103.
   PubMed Web of Science ®Google Scholar
• Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010;28:791–799.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Lee JH, Kim SY, Kun N, Kuh HJ. Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Sci 2008;99:423–431.
   Google Scholar